Understanding biomarkers in metastatic colorectal cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study aims to explore the evolutionary progression of metastatic colorectal cancer (mCRC) during treatment. This prospective observational study will analyze genetic heterogeneity across different metastatic sites and assess the role of circulating tumor DNA (ctDNA) as a biomarker for treatment response. By examining the tumor microenvironment and immune cell interactions, the study seeks to uncover mechanisms behind therapeutic failures in mCRC patients. The findings could lead to more personalized treatment strategies for patients undergoing chemotherapy and surgical interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of synchronous metastatic colorectal cancer, planned cancer treatment with curative intent at the Skåne University Hospital

Exclusion Criteria:

* Not accepting the study inclusion terms (informed consent not obtained)
* Age below or above the age limit

Where it's running

• Department of Oncology, Hematology and Radiophysics, Skane University Hospital
  Lund, Skåne County, Sweden Recruiting
• Department of Oncology, Hematology and Radiophysics, Skane University Hospital
  Malmö, Skåne County, Sweden Recruiting

Study contacts

• Study coordinator: Danyil Kuznyecov, M.D.
• Email: danyil_szergejevics.kuznyecov@med.lu.se
• Phone: +46 725972072

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant therapy followed by local treatment for recurrent colorectal liver metastases

  This study is testing if giving a new treatment before local therapy can help people with recurrent colorectal liver cancer live longer compared to getting local therapy right away.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05861505

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Can hepatic artery infusion chemotherapy enable liver surgery for colorectal cancer that has spread to the liver?

  This study tests whether hepatic artery infusion chemotherapy plus standard chemotherapy can make some inoperable colorectal liver metastases operable in patients.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07764497

• Immunotherapy plus Simvastatin and Targeted Therapy with Chemotherapy for Advanced Colorectal Cancer

  This trial tests whether adding immune therapy (adbelimumab? actually Adebrelimab) with simvastatin and targeted therapy to standard chemotherapy helps people with metastatic colorectal cancer that is MSI-H/dMMR or MSS/pMMR depending on combination.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu and 1 other locations · NCT07718490

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.